CXCR4 signaling determines the fate of hematopoietic multipotent progenitors by stimulating mTOR activity and mitochondrial metabolism.


Journal

Science signaling
ISSN: 1937-9145
Titre abrégé: Sci Signal
Pays: United States
ID NLM: 101465400

Informations de publication

Date de publication:
29 Oct 2024
Historique:
medline: 29 10 2024
pubmed: 29 10 2024
entrez: 29 10 2024
Statut: ppublish

Résumé

Both cell-intrinsic and niche-derived, cell-extrinsic cues drive the specification of hematopoietic multipotent progenitors (MPPs) in the bone marrow, which comprise multipotent MPP1 cells and lineage-restricted MPP2, MPP3, and MPP4 subsets. Patients with WHIM syndrome, a rare congenital immunodeficiency caused by mutations that prevent desensitization of the chemokine receptor CXCR4, have an excess of myeloid cells in the bone marrow. Here, we investigated the effects of increased CXCR4 signaling on the localization and fate of MPPs. Knock-in mice bearing a WHIM syndrome-associated

Identifiants

pubmed: 39471249
doi: 10.1126/scisignal.adl5100
doi:

Substances chimiques

TOR Serine-Threonine Kinases EC 2.7.11.1
Receptors, CXCR4 0
mTOR protein, mouse EC 2.7.1.1
CXCR4 protein, mouse 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

eadl5100

Auteurs

Vincent Rondeau (V)

Université Paris Cité, Institut de Recherche Saint-Louis, INSERM U1160, Paris, France.
OPALE Carnot Institute, Organization for Partnerships in Leukemia, Hôpital Saint-Louis, Paris, France.

Maria Kalogeraki (M)

Université Paris Cité, Institut de Recherche Saint-Louis, INSERM U1160, Paris, France.
OPALE Carnot Institute, Organization for Partnerships in Leukemia, Hôpital Saint-Louis, Paris, France.

Lilian Roland (L)

Université Paris Cité, Institut de Recherche Saint-Louis, INSERM U1160, Paris, France.
OPALE Carnot Institute, Organization for Partnerships in Leukemia, Hôpital Saint-Louis, Paris, France.

Zeina Abou Nader (ZA)

Université Paris Cité, Institut de Recherche Saint-Louis, INSERM U1160, Paris, France.
OPALE Carnot Institute, Organization for Partnerships in Leukemia, Hôpital Saint-Louis, Paris, France.

Vanessa Gourhand (V)

Université Paris Cité, Institut de Recherche Saint-Louis, INSERM U1160, Paris, France.
OPALE Carnot Institute, Organization for Partnerships in Leukemia, Hôpital Saint-Louis, Paris, France.

Amélie Bonaud (A)

Université Paris Cité, Institut de Recherche Saint-Louis, INSERM U1160, Paris, France.
OPALE Carnot Institute, Organization for Partnerships in Leukemia, Hôpital Saint-Louis, Paris, France.

Julia Lemos (J)

Université Paris Cité, Institut de Recherche Saint-Louis, INSERM U1160, Paris, France.
OPALE Carnot Institute, Organization for Partnerships in Leukemia, Hôpital Saint-Louis, Paris, France.

Mélanie Khamyath (M)

Université Paris Cité, Institut de Recherche Saint-Louis, INSERM U1160, Paris, France.
OPALE Carnot Institute, Organization for Partnerships in Leukemia, Hôpital Saint-Louis, Paris, France.

Clémentine Moulin (C)

Université Paris Cité, Institut de Recherche Saint-Louis, INSERM U1160, Paris, France.
OPALE Carnot Institute, Organization for Partnerships in Leukemia, Hôpital Saint-Louis, Paris, France.

Bérénice Schell (B)

Université Paris Cité, Institut de Recherche Saint-Louis, INSERM U1160, Paris, France.
OPALE Carnot Institute, Organization for Partnerships in Leukemia, Hôpital Saint-Louis, Paris, France.

Marc Delord (M)

Direction à la Recherche Clinique et à l'Innovation, Centre Hospitalier de Versailles, Le Chesnay, France.

Ghislain Bidaut (G)

Aix-Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France.

Séverine Lecourt (S)

INSERM U1279, Gustave Roussy Cancer Center, Université Paris Saclay, Villejuif, France.

Christelle Freitas (C)

Université Paris Cité, Institut de Recherche Saint-Louis, INSERM U1160, Paris, France.
OPALE Carnot Institute, Organization for Partnerships in Leukemia, Hôpital Saint-Louis, Paris, France.

Adrienne Anginot (A)

Université Paris Cité, Institut de Recherche Saint-Louis, INSERM U1160, Paris, France.
OPALE Carnot Institute, Organization for Partnerships in Leukemia, Hôpital Saint-Louis, Paris, France.

Nathalie Mazure (N)

Centre Méditerranéen de Médecine Moléculaire, INSERM U1065, Nice, France.

David H McDermott (DH)

Molecular Signaling Section, Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA.

Véronique Parietti (V)

Université Paris Cité, UMS Saint-Louis INSERM U53/UAR2030, Paris, France.

Niclas Setterblad (N)

Université Paris Cité, UMS Saint-Louis INSERM U53/UAR2030, Paris, France.

Nicolas Dulphy (N)

Université Paris Cité, Institut de Recherche Saint-Louis, INSERM U1160, Paris, France.
OPALE Carnot Institute, Organization for Partnerships in Leukemia, Hôpital Saint-Louis, Paris, France.

Françoise Bachelerie (F)

Université Paris-Saclay, INSERM, Inflammation, Microbiome and Immunosurveillance, Orsay, France.

Michel Aurrand-Lions (M)

OPALE Carnot Institute, Organization for Partnerships in Leukemia, Hôpital Saint-Louis, Paris, France.
Aix-Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France.

Daniel Stockholm (D)

PSL Research University, EPHE, Paris, France.
Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine (CRSA), Paris, France.

Camille Lobry (C)

Université Paris Cité, Institut de Recherche Saint-Louis, INSERM U944, Paris, France.

Philip M Murphy (PM)

Molecular Signaling Section, Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA.

Marion Espéli (M)

Université Paris Cité, Institut de Recherche Saint-Louis, INSERM U1160, Paris, France.
OPALE Carnot Institute, Organization for Partnerships in Leukemia, Hôpital Saint-Louis, Paris, France.

Stéphane J C Mancini (SJC)

Univ Rennes, INSERM, EFS, UMR S1236, Rennes, France.

Karl Balabanian (K)

Université Paris Cité, Institut de Recherche Saint-Louis, INSERM U1160, Paris, France.
OPALE Carnot Institute, Organization for Partnerships in Leukemia, Hôpital Saint-Louis, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH